Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calibrant Biosystems has entered into research collaboration with the Yale University School of Medicine to identify novel ovarian and breast cancer drug targets from clinical tissue specimens using the company's Gemini proteomics platform.
Subscribe to our email newsletter
Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression.
Fattaneh Tavasolli, Calibrant’s collaborator at the Yale University School of Medicine, said: “This partnership is enabling effective identification of disease-relevant pathways and drug targets by applying Calibrant’s Gemini platform to targeted discovery from selected cancer cells.”